DalCor Pharmaceuticals Lands $150,000,000 Series B Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6dda61a3-9036-4814-8191-9cff6fe0f8b2 - Date
4/20/2016 - Company Name
DalCor Pharmaceuticals - Mailing Address
400 S. El Camino Real San Mateo, CA 94402 USA - Company Description
DalCor is focused on providing precision medicine through identification of genetically distinct patient populations that derive clinical benefits. By integrating clinical, biologic and genetic insights, DalCor intends to deliver superior outcomes in clinical medicine. - Website
http://www.dalcorpharma.com - Transaction Type
Venture Equity - Transaction Amount
$150,000,000 - Transaction Round
Series B - Proceeds Purposes
DalCor will use the proceeds to fund a Phase 3 clinical trial of dalcetrapib, a CETP inhibitor, in patients who have recently experienced Acute Coronary Syndrome (ACS). - M&A Terms
- Venture Investor
Sanderling Ventures - Venture Investor
Investor - Venture Investor
Fonds de solidarite FTQ - Venture Investor
CTI Life Sciences Fund - Venture Investor
CDC – Caisse des Depots - Venture Investor
Undisclosed
